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Multiple myeloma (MM) is a rare malignancy, characterized by 
clonal proliferation of plasma cells. Monoclonal immunoglobulin 
(paraprotein), secreted by plasmocytes, can cause plasma 
hyperviscosity and renal damage. Proliferation of plasma cells 
can lead to bone marrow suppression and cause hypercalcaemia. 
These features of MM give rise to different symptoms, such as 
bone pain from direct skeletal involvement, fatigue from anemia, or 
headache from hyperviscosity. The incidence of MM is estimated at 
4.5‑6/100 000 [1]. It mostly (90%) affects people above 50 years of age 
(median 70 years), more often men (M/W = 1.21) [2].
The diagnosis of MM requires detection of clonal plasma cells in 
histopathologic and immunophenotypic examination of bone marrow 
or in extramedullary plasmacytic tumor biopsy. Blood examination 
reveals increased total protein concentration and presence of 
monoclonal protein, as well as hypercalcaemia (in 30% of patients), 
increased uric acid concentration (50%), creatinine (35%), C-reactive 
protein, beta-2 microglobulin and lactate dehydrogenase. Erythrocyte 
sedimentation rate over 40 mm/1h is typical for MM (84%). Complete 
blood count (CBC) abnormalities include normocytic anemia 
(ca 70%), rouleaux-forming erythrocytes (50%), leukopenia and 
thrombocytopenia (20% and 5%, respectively) [1, 2].
It is known that plasma cell dyscrasias can be accompanied by both 
thrombotic and hemorrhagic events, including venous thrombosis, 
acquired von Willebrand syndrome and acquired hemophilia. 
Increased risk of venous thromboembolism in myeloma patients is 
associated with increased FVIII and von Willebrand factor activity 
[3, 4, 5], decreased protein S activity [3] and acquired resistance 
to activated protein C [6]. Bleeding occurs in approximately 15% 
of patients with IgG and more than 30% of patients with IgA 
and IgM monoclonal proteins [7, 8]. Coagulation defects that result in 
bleeding diathesis are caused by a variety of mechanisms, including 
coagulation factor deficiencies due to amyloid adsorption [9], 
production of paraproteins with inhibitory activity toward coagulation 
factors [10, 11], e.g. von Willebrand factor [12], circulating proteins 
with heparin‑like activity [13], impaired fibrin monomer polymerization 
[14–17] or systemic fibrinolysis [18]. Abnormal screening coagulation 
test results, including prothrombin time (PT), activated partial 
thromboplastin time (APTT), and thrombin time (TT), are commonly 
encountered in patients with plasma cell neoplasms and are not 
typically associated with clinically significant bleeding [4, 5].
We describe a patient who was accidentally diagnosed with multiple 
myeloma during diagnostic work-up of screening coagulation tests 
prolongation. A 71-year-old patient diagnosed with renal tumor was 
referred to the hematologist due to abnormal results of pre-surgery 
screening tests: PT (1,25 INR, normal range: 0.85-1.15), APTT (42 s, 
normal range: 25.0-33.5) and TT (58 s, normal range: 14.0-21.0). 
Fibrinogen level, transaminase activities and CBC (complete blood 
count) were normal. No bleeding symptoms were present neither at 
presentation nor in the past. Teeth extractions were uncomplicated 
as well as cataract surgery, despite documented abnormalities in 
coagulation tests. The patient complained of no symptoms. He 
suffered from benign prostatic hyperplasia, treated with finasteride. 
He was also taking numerous herbs and dietary supplements at his 
own discretion: saw palmetto, vitamin E, vitamin C, magnesium, 
sodium bicarbonate, curcuma and olive oil with lemon.
Laboratory analysis confirmed previous findings: PT was 14 s (1.25 
INR), APTT 42.5 s and TT 60.2 s with normal fibrinogen concentration 
assessed with both Clauss method (2.2 g/L, normal range: 
1.8-3.5) and nephelometry (3.1 g/L, normal range: 1.8-3.5). Results 
of repeated tests, performed after 2 weeks wash-out from all 
over‑the‑counter preparations, were not different. Coagulation factors 
activity was normal [table I]. Batroxobin time (BT) and D-dimer were 
normal (18.9 s, normal range: 16.0-22.0 and < 0.17 mg/L, normal 
range: < 0.55, respectively). All coagulometric parameters were 
performed using Siemens kits with BCS XP analyzer (Siemens, 
Germany). Due to significant disproportion of TT and BT values 
dabigatran plasma concentration was measured with Innovance DTI 
Assay (Siemens, Germany) and yielded a positive result: 31 ng/ mL 
(near the lower limit of measuring range). The patient and his 
family denied dabigatran intake, therefore a false positive result was 
suspected. Further diagnostics included antiphospholipid antibodies 
and paraprotein assessment. Presence of lupus anticoagulant 
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and IgG/IgM anticardiolipin antibodies was excluded. Total protein 
concentration was significantly increased (91.6 g/L, normal range: 
66.0-87.0) and monoclonal beta-globulin was detected (43.2 g/L) 
(Fig. 1). Serum calcium concentration was increased to 2.73 mmol/L 
(normal range: 2.15‑2.55). Serum immunofixation test showed kappa 
immunoglobulin G. Urine examination also revealed the presence of 
monoclonal light chains. Bone marrow histopathology showed diffuse 
(80%) infiltration of atypical plasma cells. Computed tomography 
detected multiple osteolytic lesions of the spine and flat bones, as 
well as fractures of L3 and L4 vertebrae. Analysis of chromosomes 
stained by the GTG and FISH stripes showed: 46, XY[20] nuc ish 
(IGH, TP53, D17Z10x2[200]. Multiple myeloma IgG kappa was 
diagnosed, ISS (International Staging System) stage II. After four 
VTD cycles (thalidomide, dexamethasone, bortezomib) the patient 
achieved partial remission of MM.
Discussion
Numerous studies addressed the issue of abnormal screening 
coagulation tests in asymptomatic patients with multiple myeloma 
and other plasma cell neoplasms. Post et al. [19] and Xin-yao [20] 
showed that the PT, but not  APTT, was positively correlated with serum 
paraprotein level, regardless of the reagents and instrumentation 
used to assess clotting time. Huang et al. [21] and Pandey 
et al. [22] confirmed this finding and, more importantly, showed a 
strong correlation between TT prolongation and total light chain (not 
M protein) concentration. Prolonged TT most likely results from 
acquired dysfibrinogenemia, secondary to multiple myeloma. Fibrin 
polymerization induced by thrombin was impaired by paraprotein, 
interacting with γ‑chain of the fibrinogen molecule [23]. Light chain 
paraprotein might have a stronger nonspecific binding effect to 
fibrinogen and can affect TT more likely than other immunoglobulin 
types. In most cases TT prolongation was accompanied by a 
prolonged PT, suggesting that TT is more sensitive to the presence 
of monoclonal protein than PT [22]. This hypothesis is in line 
with our observations. All three screening tests (PT, APTT, TT) 
were prolonged, but TT to the greatest extend (almost 3 times). We 
also measured BT that evaluates the same part of the coagulation 
process with the use of batroxobin instead of thrombin (batroxobin is 
a proteolytic snake venom enzyme, inducing coagulation by cleavage 
of fibrinopeptide A from fibrinogen). Disproportion between TT and 
BT is typical for dysfibrinogenemia, heparin therapy and also for the 
Table I. Results of laboratory parameters measured before the diagnosis of multiple myeloma
Test I visit II visit Reference range
PT (sec) 14.0 13.5 9.8-12.1
PT (INR) 1.30 1.20 0.85-1.15
APTT (sec) 42.5 40.0 25.0-33.5
TT (sec) 60.2 59.9 14.0-21.0
BT (sec) 18.9 18.7 16.0-22.0
Fibrinogen (Clauss method, g/L) 2.0 2.2 1.8-3.5
Fibrinogen (nephelometric method, g/L) 3.1 1.8-3.5
D-dimer (mg/L) < 0.17 < 0.55
Factor II (%) 116.1 50-150
Factor V (%) 126.2 50-150
Factor VIII (%) 103.8 50-150
Factor IX (%) 122.8 50-150
Factor X (%) 94.2 50-150
Factor XI (%) 82.6 50-150
Factor XII (%) 58.0 50-150
GGTP (U/L) 11 8-61
Cholinesterase (U/L) 7622 5320-12920
LDH (U/l) 119 135-225
Lupus anticoagulant negative negative
Anticardiolipin antibodies IgG (GPL) 2.5 < 10
Anticardiolipin antibodies IgM (MPL) 1.3 < 20
Calcium (mmol/L) 2.73 2.15-2.55
Total protein (g/L) 91.6 66.0-87.0
Monoclonal protein (g/L) 43.2 0
Beta-2 microglobulin 2.23 1.09-2.53
Abbreviations: PT – prothrombin time; APTT – activated partial thromboplastin time; TT – thrombin time; BT – batroxobine time; GGTP  – gamma-glutamyl transpeptidase; LDH – 
lactate dehydrogenase.
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presence of paraprotein (no interaction with thrombin is detected). 
The same disproportion is visible during dabigatran therapy; this is 
why we decided to perform the dilute thrombin assay. Its abnormal 
result can be explained by a similar interference to that observed in 
the TT assay (the presence of paraprotein impaired thrombin induced 
fibrin polymerization).
We noticed a small disproportion in fibrinogen levels measured with two 
different methods (functional Clauss assay and nephelometric test), 
with both results remaining in the reference range (2.2 g/L and 3.1 g/L). 
It may likely reflect an acquire dysfibrinogenemia state, observed 
sometimes in patients with MM [23]. Richter et al. [24] suggest that 
light chain paraprotein is not prone to inhibit coagulation factors, 
accordingly this was not the reason of coagulation tests prolongation 
in our patient (all clotting factors activities remained normal).
It is worth emphasizing that the results of coagulation assays does 
not always reflect the real coagulation status in vivo. Coagulation 
disturbances, however, tend to increase with the progress of the 
disease [25].
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